asal ganglia are the third most common site for intracranial germ cell tumors (GCTs) to develop, following the pineal region and neurohypophysis. 8 The extent of GCTs in the basal ganglia is difficult to evaluate compared with those in other regions because the former show only a subtle signal change on MRI, especially at an early stage.
dedicated PET/CT scanners (Biograph 6 and 16, Siemens Japan Ltd.). Different MET doses were injected according to age: 0-4 years, 91 MBq; 5-9 years, 180 MBq; 10-14 years, 271 MBq; 15 years and older, 6 MBq/kg. The CT acquisition parameters were 5-mm-thick transaxial images at 130 kV and 120 mA for the head and neck and 130 kV and 50 mA for the body.
Images were reconstructed using a combination of Fourier rebinning and the ordered subset expectation maximization at iteration 3 with 8 subsets. The PET images were corrected for attenuation based on CT data. Volumes of interest were set manually on the brain regions. We evaluated the MET uptake of the lesion as the maximum standardized uptake value (SUVmax) and tumor/normal (T/N) gray matter ratio.
On posttreatment assessment, the patients underwent PET scanning within 1 month after the final chemotherapy course.
case reports
The diagnoses, tumor characteristics, and outcomes in our 3 patients are shown in Table 1 . Progression-free survival was defined as the probability of being alive and free of progression or relapse.
case 1
A germinoma in the left basal ganglia had been diagnosed in a 14-year-old boy. At the time, he was solely treated with chemotherapy consisting of carboplatin (450 mg/m 2 /day) on Day 1 and etoposide (150 mg/m 2 /day) on Days 1-3 (carboplatin and etoposide [CARE] regimen), but the tumor recurred after 1 year. He received extended local radiotherapy of 46 Gy for the recurrent tumor. However, generalized seizures developed and a second relapse occurred when the patient was 22 years old. Brain MRI revealed a diffuse enhanced lesion along the walls of both of his lateral ventricles (Fig. 1A) . Serum human chorionic gonadotropin (HCG) and a-fetoprotein (AFP) levels were within normal limits, although the concentration of free HCG b-subunit in CSF was elevated to 0.15 ng/ml. MET-PET revealed high tracer uptake (SUVmax 3.3 and T/N ratio 1.4) at the enhanced lesion and its surroundings ( Fig. 1B and C 1D) and disappearance of the tumor after the third course (Fig. 1E) . MET-PET after all the treatments still demonstrated a mild accumulation of MET in the bilateral basal ganglia (SUVmax 2.2, T/N ratio 1.0; Fig. 1F ). However, even without any additional treatment, the patient did not experience any further recurrence for 56 months from the second relapse.
case 2
A 17-year-old boy was admitted to our hospital with the chief complaint of right hemiparesis. Brain MRI showed a large tumor (6 cm) in the left basal ganglia that extended to the temporal subcortical area. His serum total HCG level was elevated to 105.6 mIU/ml, although his serum AFP level was not elevated. He underwent partial removal of the tumor via craniotomy, and the pathological diagnosis was germinoma. MET-PET showed increased tracer uptake (SUVmax 4.2, T/N ratio 2.1; Fig. 2A -C) after the operation. Brain MRI after the first course of chemotherapy revealed significant shrinkage of the tumor (Fig. 2D) , and the patient's serum HCG level had decreased to normal levels. He underwent 3 courses of the CARE regimen and whole-brain radiotherapy (total 24 Gy). After completion of the treatments, MET-PET revealed residual accumulation (SUVmax 2.4, T/N ratio 1.0) along the left posterior limb of the internal capsule, although the tumor had disappeared on MRI, except for an unenhanced scar in the left temporal subcortical area ( Fig. 2E and F) . The patient was in complete remission for 52 months from the start of treatment.
case 3
Choriocarcinoma occurred in a 7-year-old boy who developed precocious puberty within 3 months. Although he had undergone total removal of the tumor at another hospital, the lesion recurred 3 months later because he had not received any postoperative chemotherapy and/or radiotherapy. He was referred to our hospital, and MRI at that time demonstrated a circular enhanced lesion in the left basal ganglia (Fig. 3A) . MET-PET revealed increased MET uptake by the tumor (SUVmax 2.5, T/N ratio 3.4; Fig. 3B) . His serum HCG level was elevated to 464 mIU/ ml from the start of treatment. He had a significant reduction in tumor size and normalization of the tumor marker after the first course of chemotherapy (ICE regimen) and radiotherapy (craniospinal radiation 30 Gy, local boost radiation 60 Gy total; Fig. 3C ). Although he received 8 courses of the ICE regimen and his clinical course was uneventful, the minimally enhanced mass showed no changes on MRI from the end of the third chemotherapy course to the completion of treatment (Fig. 3D) . MET-PET uptake by residual lesion was observed (SUVmax 1.4, T/N ratio 1.2; Fig. 3E ). However, the patient was free of any signs of recurrence without further treatment for 44 months from the start of treatment. Follow-up MET-PET studies showed no significant changes in radiological findings at 1 month (SUVmax 1.2, T/N ratio 1.05) or 4 months (SUVmax 1.7, T/N ratio 1.16) after the end of treatments.
discussion
In this report, we describe 3 cases of basal ganglia GCT with residual uptake of MET on PET that did not indicate tumor residue. Several previous studies have reported the usefulness of MET-PET in the diagnosis of basal ganglia GCTs.
1,2,4,9 Sudo et al. 9 described a patient with a basal ganglia germinoma who developed slowly progressive hemiparesis. The apparent MET uptake on PET allowed for a precise biopsy, although MRI had shown only a minor signal change on T2-weighted imaging and no enhancement of the lesion. Hence, MET-PET may be able to detect a more exact extent of basal ganglia GCTs than MRI.
Nonetheless, whether MET-PET is useful for the posttreatment assessment of basal ganglia GCTs remains uncertain. In fact, MET uptake remained in the lesion after treatment in many of the previously reported cases. 3, 4, 9 The residual MET uptake may indicate disorders other than residual tumor. Several disorders such as cerebral infarction 5 or radiation necrosis 7 also show signs of high MET uptake because the tracer accumulates in the lesion of inflammatory change and reactive gliosis. 7 Because basal ganglia are one of the most important regions of the brain in which several neuronal pathways penetrate, overtreatment of tu- mors in this area should be avoided, especially additional radiotherapy, including stereotactic radiotherapy or radiosurgery, which can directly affect a patient's quality of life. MET uptake does not necessarily correspond to tumor residue when posttreatment assessment of basal ganglia GCTs is performed, especially in cases when a tumor's response to treatment is clearly observed.
Treatment strategies based on MET uptake should be carefully designed in patients with basal ganglia GCTs to avoid overtreatment and its complications. The T/N ratio may be a more reliable indicator of tumor activity than SUVmax or visual assessment given that T/N ratios in 2 of our 3 cases were normalized after treatment (Table 1 ). Efforts that allow the detection of minimal residual disease in intracranial GCTs should be continued.
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